jumping in here. Been using semaglutide since April. 36kg down. Novo market wegovy as “WL” so can charge what they like, despite same active ingredients.
FYI Trizepatide (Mounjaro) recently approved by TGA for sleep apnoea. Lot of murmuring around the traps about bringing it on PBS in a few years.
FYI Trizepatide (Mounjaro) recently approved by TGA for sleep apnoea. Lot of murmuring around the traps about bringing it on PBS in a few years.
October 21, 2025 at 11:45 AM
Everybody can reply
2 likes
Alcohol, nicotine and more — could drugs like Ozempic curb the desire for vices?
Studies combing through past patient data have made a similar link between drugs like Ozempic and a loss of appetite for more than just food.
#cbc #cbc-top-stories #Canada
Studies combing through past patient data have made a similar link between drugs like Ozempic and a loss of appetite for more than just food.
#cbc #cbc-top-stories #Canada
October 21, 2025 at 8:05 AM
Everybody can reply
I'm about two months on semaglutide (Ozempic/Wegovy) and while it hasn't had tremendous impact on my weight yet it does appear to have fixed my ADHD symptoms?!
October 21, 2025 at 6:07 AM
Everybody can reply
5 likes
tЯ☭mp’s economy is the new GLP-1 or semaglutide
Prices will force people to go hungry, lose shelter, housing, clothing, healthcare, weight, etc…
Prices will force people to go hungry, lose shelter, housing, clothing, healthcare, weight, etc…
October 21, 2025 at 2:43 AM
Everybody can reply
2 likes
The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events in high-risk patients with diabetes, whether or not they've had such an event already, Novo Nordisk announced.
https://www.medpagetoday.com/cardiology/generalcardiology/118042
https://www.medpagetoday.com/cardiology/generalcardiology/118042
FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular Protection
Oral semaglutide achieves a first for this drug class
www.medpagetoday.com
October 21, 2025 at 1:25 AM
Everybody can reply
2 likes
1 saves
FDA approves Novo Nordisk’s Rybelsus (oral semaglutide) to cut major heart risks in adults with type 2 diabetes. The SOUL trial showed a 14% reduction in cardiovascular events.
jcst2d.com/index.php/ne...
#Type2Diabetes #Rybelsus #HeartHealth #NovoNordisk
jcst2d.com/index.php/ne...
#Type2Diabetes #Rybelsus #HeartHealth #NovoNordisk
October 20, 2025 at 10:42 PM
Everybody can reply
🚨The November 2025 issue of Diabetes has arrived!
🔗http://diabetesjournals.org/diabetes/issue/74/11
Explore the latest research on #diabetes, including:
✨Sustained Weight Loss w/ LEAP2 and Semaglutide
✨Loss of Insulin-+ Cell Clusters & decrease in islet frequency
✨& more!
🔗http://diabetesjournals.org/diabetes/issue/74/11
Explore the latest research on #diabetes, including:
✨Sustained Weight Loss w/ LEAP2 and Semaglutide
✨Loss of Insulin-+ Cell Clusters & decrease in islet frequency
✨& more!
October 20, 2025 at 7:15 PM
Everybody can reply
Very interesting tidbit emerging from this article: That Vimy Pharma’s generic #semaglutide is "set to be" the first commercial product of Edmonton non-profit Applied Pharmaceutical Innovation (API), that received govt💰to "increase Canada’s capacity to develop and manufacture critical medicines".
October 20, 2025 at 6:44 PM
Everybody can reply
2 reposts
1 likes
Wondering what odds are of success for a brand-new Canadian company planning to apply to make generic #semaglutide as its 1st product when multiple big companies already have applications in?
"Canadian firm enters race to bring generic Ozempic to market" www.theglobeandmail.com/business/art...
"Canadian firm enters race to bring generic Ozempic to market" www.theglobeandmail.com/business/art...
Canadian firm enters race to bring generic Ozempic to market
Ozempic and Wegovy lose market exclusivity in January, clearing the way for generic formulations of semaglutide
www.theglobeandmail.com
October 20, 2025 at 6:14 PM
Everybody can reply
1 quotes
1 likes
Canadian firm enters race to bring generic Ozempic to market https://www.theglobeandmail.com/business/article-generic-ozempic-semaglutide-vimy-pharma-made-in-canada/
𝗠𝗼𝗿𝗲 𝗻𝗲𝘄𝘀 ⇢ CanadaHealthwatch.ca 🍁
𝗠𝗼𝗿𝗲 𝗻𝗲𝘄𝘀 ⇢ CanadaHealthwatch.ca 🍁
October 20, 2025 at 4:34 PM
Everybody can reply
1 reposts
12 likes
Novo Nordisk’s Missed Fee Triggers Early Semaglutide Patent Expiry in Canada - WebProNews: Novo Nordisk’s Missed Fee Triggers Early Semaglutide Patent Expiry in Canada WebProNews
Novo Nordisk’s Missed Fee Triggers Early Semaglutide Patent Expiry in Canada - WebProNews
Novo Nordisk’s Missed Fee Triggers Early Semaglutide Patent Expiry in Canada WebProNews
news.google.com
October 20, 2025 at 3:57 PM
Everybody can reply
The Obesity treatment of Semaglutide or GLP-1 pharmaceutical companies have new competition…
…the tЯ☭mp economy
…the tЯ☭mp economy
October 20, 2025 at 2:18 PM
Everybody can reply
1 likes
BTW there are also other ns-MRAs apart from Finerenone
See from our previous rant; www.nephjc.com/news/2024/10...
I think Hiddo is presenting MIRO-CKD data on Saturday at #KidneyWk
See from our previous rant; www.nephjc.com/news/2024/10...
I think Hiddo is presenting MIRO-CKD data on Saturday at #KidneyWk
October 20, 2025 at 11:28 AM
Everybody can reply
Novo Nordisk to Unveil Groundbreaking Oral Semaglutide Data at ObesityWeek 2025#USA#Atlanta#Semaglutide#Novo_Nordisk#Wegovy
Novo Nordisk to Unveil Groundbreaking Oral Semaglutide Data at ObesityWeek 2025
Novo Nordisk announces new findings on oral semaglutide at ObesityWeek 2025, shedding light on its impact on cardiometabolic health and women's wellbeing.
third-news.com
October 20, 2025 at 11:20 AM
Everybody can reply
Novo Nordisk Unveils New Insights on Oral Semaglutide at ObesityWeek 2025#United_States#Atlanta#Novo_Nordisk#Wegovy#CagriSema
Novo Nordisk Unveils New Insights on Oral Semaglutide at ObesityWeek 2025
Novo Nordisk is set to share groundbreaking data on oral semaglutide 25 mg at ObesityWeek 2025, showcasing significant findings on obesity treatments.
third-news.com
October 20, 2025 at 11:14 AM
Everybody can reply
Novo Nordisk and D Young defend crucial patent for tablet form of semaglutide - JUVE Patent: Novo Nordisk and D Young defend crucial patent for tablet form of semaglutide JUVE Patent
Novo Nordisk and D Young defend crucial patent for tablet form of semaglutide - JUVE Patent
Novo Nordisk and D Young defend crucial patent for tablet form of semaglutide JUVE Patent
news.google.com
October 20, 2025 at 11:05 AM
Everybody can reply
US consumers frequently eye Canada for cheaper medication. A patent lapse could make semaglutide more accessible there, potentially increasing cross-border 'medical tourism' or demand for mail-order imports. #DrugPricing 4/6
October 20, 2025 at 10:00 AM
Everybody can reply
If the semaglutide patent truly lapsed, Canada could see generic versions of Ozempic much sooner. This offers a rare opportunity for increased competition, potentially driving down prices for Canadian patients. #CanadianHealthcare 3/6
October 20, 2025 at 10:00 AM
Everybody can reply
Novo Nordisk's semaglutide patent in Canada lapsed due to an unpaid fee. The Hacker News debate asks: oversight or strategic move? This incident could reshape drug pricing & availability in Canada and impact US consumers seeking cheaper options. #DrugPatents 1/6
October 20, 2025 at 10:00 AM
Everybody can reply
Nope! Only side effect I’ve had has been mild constipation
I tried semaglutide tablets before and was soo nauseated, this has basically no side effects in comparison
I tried semaglutide tablets before and was soo nauseated, this has basically no side effects in comparison
October 20, 2025 at 4:33 AM
Everybody can reply
#GLP1 💉4 Week Update:
Officially, I've lost 7 lbs in 4 weeks on the #semaglutide injections. 🎉
I didn't exercise, but I modified my diet to reduce carbs and increase my plain water intake. No nasty side effects so far.
I upped my dosage yesterday and will stay on that for the next 4 weeks.
Officially, I've lost 7 lbs in 4 weeks on the #semaglutide injections. 🎉
I didn't exercise, but I modified my diet to reduce carbs and increase my plain water intake. No nasty side effects so far.
I upped my dosage yesterday and will stay on that for the next 4 weeks.
October 19, 2025 at 11:28 PM
Everybody can reply
10 likes
📰 Ozempic's Patent Expires in January: Novo Nordisk's Canadian Mistake
💬 Novo let their Canadian semaglutide patent lapse due to unpaid fees. Worth $500, they clearly underestimated market potential. 🤦♂️
https://news.ycombinator.com/item?id=45637744
💬 Novo let their Canadian semaglutide patent lapse due to unpaid fees. Worth $500, they clearly underestimated market potential. 🤦♂️
https://news.ycombinator.com/item?id=45637744
October 19, 2025 at 9:30 PM
Everybody can reply
It could, but it could also be due to perimenopause, weight loss, lower calorie intake, and/or a side effect of semaglutide
October 19, 2025 at 6:34 PM
Everybody can reply
We’d be happy for a corpulent friend who is elated having managed to lose weight and keep it under control.
But would it make no difference whether they did so through diet and exercise—just like we do—or instead took the “easy” semaglutide way?
buff.ly/l4jCVNB
But would it make no difference whether they did so through diet and exercise—just like we do—or instead took the “easy” semaglutide way?
buff.ly/l4jCVNB
October 19, 2025 at 3:09 PM
Everybody can reply
The biggest risk factor for cardiovascular disease isn’t cholesterol - it’s age.
And semaglutide is showing promise in slowing that clock.
https://longevity.direct.
And semaglutide is showing promise in slowing that clock.
https://longevity.direct.
October 19, 2025 at 11:45 AM
Everybody can reply